Oxurion NV is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Oxurion NV's ambition is to build an integrated group of subcontractors serving healthcare players. Oxurion NV holds a 72% stake in Axiodis CRO, a subcontractor specialized in biometrics.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-10	€0.003000	+15.38%	1,689,333
26-07-09	€0.002600	-7.14%	418,256
26-07-08	€0.002800	0.00%	2,770,002
26-07-07	€0.002800	0.00%	2,971,658
26-07-06	€0.002800	-6.67%	750,764

Real-time Euronext Bruxelles

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2026-07-10 EDT			5-day change	1st Jan Change
0.003000 ^EUR	+15.38%		0.00%	-58.33%

06-02	Oxurion Positions Itself in the GLP-1 Therapy Market
06-02	Oxurion Ends Talks to Buy Majority Stake in France-based CRO	MT

Market Cap	231K 264K 213K 196K 373K 25.14M 379K 2.54M 998K 12.39M 990K 968K 42.58M	P/E 2024	2.56x	P/E 2025	-0.05x
Enterprise Value	11.24M 12.85M 10.37M 9.58M 18.17M 1.23B 18.48M 124M 48.66M 604M 48.26M 47.21M 2.08B	EV / Sales 2024	3,879x	EV / Sales 2025	20.7x
Free-Float	98.88%	Yield 2024 *	-	Yield 2025	-

06-02	Oxurion Positions Itself in the GLP-1 Therapy Market
06-02	Oxurion Ends Talks to Buy Majority Stake in France-based CRO	MT
04-29	Oxurion NV Auditor Raises 'Going Concern' Doubt	CI
04-29	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-19	Oxurion NV signs a letter of intent for acquisition of an International CRO	RE
03-01	Oxurion Extends Talks for Acquisition of Majority Stake in French CRO	MT
01-19	Oxurion Temporarily Suspends Digital Assets Investment Project Amid Crypto Volatility	MT
25-10-14	Oxurion to Acquire Majority Stake in French Contract Research Organization	MT
25-10-01	Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-05	Oxurion Receives Improved EUR30 Million Indicative Financing Offer from Atlas Special	MT
25-07-22	Oxurion Plans EUR10 Million Bond Issue to Fund Treasury Diversification	MT
25-07-21	Oxurion NV announced that it expects to receive ?10 million in funding from Atlas Special Opportunities LLC	CI
25-07-17	Oxurion Secures Financing for Axiodis Stake Acquisition	MT

07-06	Oxurion Nv : Oxurion achieves another milestone in the expansion of the Exagis platform with the commercial launch of its eTMF module	AT
06-26	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT
06-24	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT
06-19	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT
06-15	Oxurion Nv : Major market validation: Pierre Fabre Laboratories uses Oxurion’s Exagis Platform	AT

Oxurion NV Stock

Stocks

OXUR

BE0974487192

Biotechnology & Medical Research

Valuation: Oxurion NV

Chart: Oxurion NV

Latest news : Oxurion NV

Press Releases: Oxurion NV

News in other languages: Oxurion NV

Quotes and Performance

Course Extremes

Managers and Directors: Oxurion NV

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

07-08	Oxurion Nv : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
07-06	Oxurion Nv : Oxurion bereikt een nieuwe mijlpaal in de uitbouw van het Exagis-platform met de commerciële lancering van zijn eTMF-module
07-06	Oxurion Nv : Oxurion franchit une nouvelle étape dans le développement de sa plateforme Exagis avec le lancement commercial de son module eTMF
06-26	Oxurion Nv : Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
06-24	Oxurion Nv : Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC

1 day	+15.38%
Current month	+7.14%
3 months	-31.82%
6 months	-60.53%
Current year	-58.33%

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.08
3 years	0		49
5 years	0		25,900
10 years	0		104,600

Manager	Title	Age	Since
Ghoson Pascal CEO	Chief Executive Officer	37	2023-12-27
Philippe Barbeaux CTO	Chief Tech/Sci/R&D Officer	-	2023-12-27
Samuel Darcheville SEC	Corporate Secretary	-	2023-12-27

Director	Title	Age	Since
Ghoson Pascal BRD	Director/Board Member	37	2023-12-27
James Hartmann BRD	Director/Board Member	60	2023-12-27
Charles Paris de Bollardire CHM	Chairman	-	2023-12-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
22-03-10	Midelco NV	Buy	Company	1,180	0.0030%
22-03-10	Ecp Liquid Fund 1 LLC	Buy	Company	1,180	0.0030%
21-11-16	Thomas Clay	Buy	Chairman	2,766	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OXURION NV	+15.38%	0.00%	-88.89%	-99.98%	264K
LONZA GROUP AG	+0.58%	+2.06%	+2.92%	+10.86%	50.44B
REVOLUTION MEDICINES, INC.	-2.11%	-1.73%	+384.96%	+586.18%	40.63B
IQVIA HOLDINGS INC.	-0.68%	+0.90%	+25.55%	-5.29%	34.88B
BEONE MEDICINES AG	-1.62%	-3.65%	+17.66%	+54.86%	33.67B
CELLTRION, INC.	+1.21%	-0.79%	+4.46%	+35.18%	26.29B
ASCENDIS PHARMA A/S	-2.71%	+0.39%	-	-	17.11B
MEDPACE HOLDINGS, INC.	-0.25%	-5.64%	+62.45%	+120.53%	15.29B
IONIS PHARMACEUTICALS, INC.	-8.22%	-29.43%	+38.51%	+40.50%	10.62B
EUROFINS SCIENTIFIC SE	+0.23%	-0.58%	+13.76%	+21.11%	13.74B
Average	+0.20%	-3.24%	+51.26%	+84.88%	24.27B
Weighted average by Cap.	-0.94%	-0.03%	+83.99%	+130.86%

	2024	2025
Net sales	3K 3.43K 2.77K 2.56K 4.85K 327K 4.93K 33.06K 12.98K 161K 12.88K 12.6K 554K	555K 635K 512K 473K 897K 60.52M 912K 6.12M 2.4M 29.81M 2.38M 2.33M 102M
Net income	119K 136K 110K 101K 192K 12.98M 196K 1.31M 515K 6.39M 511K 500K 21.97M	-3.73M -4.26M -3.44M -3.18M -6.03M -406M -6.13M -41.09M -16.13M -200M -16M -15.65M -688M
Net Debt	10.87M 12.43M 10.03M 9.26M 17.57M 1.19B 17.87M 120M 47.05M 584M 46.67M 45.65M 2.01B	11.01M 12.59M 10.16M 9.38M 17.8M 1.2B 18.1M 121M 47.66M 592M 47.27M 46.24M 2.03B